Showing results (1-10 of 41) with videos related to

Sort By:
Pageof 5
Statistics in Medicine|September 28, 2004
Including a time-of-year effect in the analysis of a matched case-control studyNigel Stallard, Lee Tombs
Advances in Therapy|September 8, 2018
Preventing Clinically Important Deterioration of COPD with Addition of Umeclidinium to Inhaled Corticosteroid/Long-Acting β2-Agonist Therapy: An Integrated Post Hoc AnalysisIan P Naya, Lee Tombs, David A Lipson, et al.
Pulmonary Pharmacology & Therapeutics|July 15, 2014
A randomized, placebo- and moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjectsDennis Kelleher, Lee Tombs, Andrew Preece, et al.
Clinical Therapeutics|December 4, 2012
Influence of renal and hepatic impairment on the pharmacokinetic and pharmacodynamic properties and tolerability of fluticasone furoate and vilanterol in combinationAnn Allen, Angela Davis, Kelly Hardes, et al.
British Journal of Clinical Pharmacology|November 3, 2012
The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of inhaled fluticasone furoate and vilanterol trifenatate in healthy subjectsRodger Kempsford, Ann Allen, Joanne Bal, et al.
Respiratory Medicine|November 9, 2013
The efficacy of once-daily fluticasone furoate/vilanterol in asthma is comparable with morning or evening dosingRodger D Kempsford, Amanda Oliver, Joanne Bal, et al.
Respiratory Research|March 28, 2019
Impact of prior and concurrent medication on exacerbation risk with long-acting bronchodilators in chronic obstructive pulmonary disease: a post hoc analysisIan Naya, Lee Tombs, David A Lipson, et al.
ERJ Open Research|February 26, 2025
Effects of seasonality and treatment on COPD clinical outcomes: IMPACT post hoc analysisGerard J Criner, David A Lipson, Lee Tombs, et al.
Respiratory Research|November 21, 2018
Long-term outcomes following first short-term clinically important deterioration in COPDIan P Naya, Lee Tombs, Hana Muellerova, et al.
Clinical Therapeutics|June 21, 2014
Effects of moderate hepatic impairment on the pharmacokinetic properties and tolerability of umeclidinium and vilanterol in inhalational umeclidinium monotherapy and umeclidinium/vilanterol combination therapy: an open-label, nonrandomized studyRashmi Mehta, Kelly Hardes, Dennis Kelleher, et al.
Pageof 5